ERs could become frontline for HIV prevention: new study tests immediate PrEP

NCT ID NCT07462611

Recruiting now Prevention Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving HIV prevention pills (PrEP) to people right in the emergency room helps them start and stay on prevention. Researchers will enroll 250 HIV-negative adults at risk for HIV in Dallas. Participants get a 30-day pill supply and a clinic appointment to continue PrEP, with the goal of keeping 50% engaged in care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tenofovir disoproxil fumarate / emtricitabine (TDF/FTC) oral pills
What this could lead to: If successful, this could show that starting HIV prevention pills immediately in the emergency room helps more people stay protected from HIV.
What could go wrong: This is a small pilot study (250 people) testing feasibility, not yet proven to work. It may not show a big enough benefit or be practical in other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Emergencies posterior leukoencephalopathy syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PRE-EXPOSURE PROPHYLAXIS PREP

Contacts and locations

Locations

Parkland Health
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.